Literature DB >> 24114049

Sustained virological response after 4 weeks of telaprevir, peginterferon, and ribavirin in an Asian patient with genotype 1 chronic hepatitis C and IL28B genotype CC.

Natalie Brulotte1, Hejin Hahn, Maximilian Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24114049     DOI： 10.1007/s10620-013-2903-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  5 in total

Review 1.  IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies.

Authors:  Paul J Clark; Alex J Thompson; John G McHutchison
Journal:  Am J Gastroenterol       Date:  2010-10-05       Impact factor: 10.864

2.  Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

Authors:  Jeremie Guedj; Alan S Perelson
Journal:  Hepatology       Date:  2011-05-02       Impact factor: 17.425

3.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

4.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

5.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425
  5 in total
  1 in total

1.  Sustained virologic response after 6 weeks of therapy with a first-generation hepatitis C virus protease inhibitor.

Authors:  Andreas Kyvernitakis; Elias Jabbour; Harrys A Torres
Journal:  Clin Infect Dis       Date:  2014-02-05       Impact factor: 9.079
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.